对非酒精性脂肪性肝病患者进行初级保健转诊路径的前瞻性评估
这项前瞻性纵向队列研究在3012例非酒精性脂肪性肝病(NAFLD)患者中评估了由Fibrosis-4评分和ELF™检测组成的2步路径。路径使用使晚期纤维化(Kleiner F3)和肝硬化检出增加5倍(OR 5.18),同时将不必要的转诊减少81%(OR 0.193)。在遵循路径的转诊中,不必要转诊从95.2%降至70.4%。
要点
- 2步路径(Fibrosis-4评分后必要时ELF™检测)使晚期纤维化和肝硬化检出增加5倍。
- 路径使用将初级保健到二级保健的不必要转诊减少81%。
- 遵循路径时,不必要转诊从79/83(95.2%)降至107/152(70.4%)。
核心结论
- 使用非侵入性血液肝纤维化检测可提高NAFLD患者晚期纤维化和肝硬化的检出,同时减少不必要的转诊。
研究设计与样本
- 前瞻性纵向队列研究,分析路径引入前后数据并与未暴露对照比较,共分析3012例患者。
主要发现
- 路径使用检出晚期纤维化(Kleiner F3)和肝硬化病例增加5倍(OR 5.18;95%CI 2.97-9.04;p<0.0001)。
- 路径使用将初级保健到二级保健的不必要转诊减少81%(OR 0.193;95%CI 0.111-0.337;p<0.0001)。
- 路径仅用于48%的转诊,但暴露于路径的实践与未暴露实践相比,不必要转诊下降77%(OR 0.23;95%CI 0.658-0.082;p=0.006),晚期纤维化和肝硬化检出提高4倍(OR 4.32;95%CI 1.52-12.25;p=0.006)。
- 与路径引入前转诊相比,不必要转诊从79/83(95.2%)降至107/152(70.4%),遵循路径时不必要转诊减少88%(OR 0.12;95%CI 0.042-0.349;p<0.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The development of non-invasive liver fibrosis tests may enable earlier identification of patients with non-alcoholic fatty liver disease (NAFLD) requiring referral to secondary care. We developed and evaluated a pathway for the management of patients with NAFLD, aimed at improving the detection of cases of advanced fibrosis and cirrhosis, and avoiding unnecessary referrals. METHODS: This was a prospective longitudinal cohort study, with analyses performed before and after introduction of the pathway, and comparisons made to unexposed controls. We used a 2-step algorithm combining the use of Fibrosis-4 score followed by the ELF™ test if required. RESULTS: In total, 3,012 patients were analysed. Use of the pathway detected 5 times more cases of advanced fibrosis (Kleiner F3) and cirrhosis (odds ratio [OR]5.18;95%CI2.97-9.04; p <0.0001), while reducing unnecessary referrals from primary care to secondary care by 81% (OR0.193; 95%CI 0.111-0.337; p <0.0001). Although it was used for only 48% of referrals, significant benefits were observed in practices exposed to the pathway compared to those which were not, with unnecessary referrals falling by 77% (OR0.23; 95% CI0.658-0.082; p = 0.006) and a 4-fold improvement in detection of cases of advanced fibrosis and cirrhosis (OR4.32; 95% CI1.52-12.25; p = 0.006). Compared to referrals made before the introduction of the pathway, unnecessary referrals fell from 79/83 referrals (95.2%) to 107/152 (70.4%), representing an 88% reduction in unnecessary referrals when the pathway was followed (OR0.12; 95%CI0.042-0.349; p <0.0001). CONCLUSIONS: The use of non-invasive blood tests for liver fibrosis improves the detection of advanced fibrosis and cirrhosis, while reducing unnecessary referrals in patients with NAFLD. This strategy improves resource use and benefits patients. LAY SUMMARY: Non-alcoholic fatty liver disease effects up to 30% of the population but only a minority of cases develop liver disease. Our study has shown that established blood tests can be used in primary care to stratify patients with fatty liver disease, leading to a reduction in unnecessary referrals by 80% and greatly improving the detection of cases of advanced fibrosis and cirrhosis.
引用
- Srivastava A, Gailer R, Tanwar S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019. PMID: 30965069. doi:10.1016/j.jhep.2019.03.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。